AnaptysBio (NASDAQ:ANAB) Shares Up 8.2%

AnaptysBio, Inc. (NASDAQ:ANAB) shares shot up 8.2% during trading on Friday . The company traded as high as $20.52 and last traded at $20.42. 253,023 shares traded hands during trading, a decline of 19% from the average session volume of 312,846 shares. The stock had previously closed at $18.87.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ANAB. Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. Wedbush upgraded AnaptysBio from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $20.00 to $34.00 in a research note on Tuesday, March 12th. Stifel Nicolaus initiated coverage on AnaptysBio in a research note on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective on the stock. Piper Sandler initiated coverage on AnaptysBio in a research report on Friday, February 16th. They set an “overweight” rating and a $80.00 target price on the stock. Finally, SVB Leerink initiated coverage on AnaptysBio in a research report on Tuesday, April 16th. They set an “outperform” rating and a $47.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.22.

AnaptysBio Price Performance

The stock has a market capitalization of $573.72 million, a P/E ratio of -3.45 and a beta of -0.30. The company has a fifty day moving average of $22.93 and a two-hundred day moving average of $20.58.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.74) by $0.15. The firm had revenue of $9.01 million during the quarter, compared to analyst estimates of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. As a group, equities research analysts predict that AnaptysBio, Inc. will post -6.17 EPS for the current fiscal year.

Insider Activity

In other news, insider Eric J. Loumeau sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the completion of the transaction, the insider now directly owns 3,240 shares of the company’s stock, valued at $81,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Dennis Mulroy sold 3,065 shares of the company’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $23.63, for a total transaction of $72,425.95. Following the completion of the transaction, the chief financial officer now directly owns 964 shares of the company’s stock, valued at $22,779.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric J. Loumeau sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the insider now owns 3,240 shares of the company’s stock, valued at $81,000. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 157,005 shares of company stock valued at $3,586,199. 35.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Fisher Asset Management LLC boosted its position in shares of AnaptysBio by 0.7% during the fourth quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after buying an additional 500 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of AnaptysBio during the first quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. boosted its position in shares of AnaptysBio by 350.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock worth $66,000 after buying an additional 2,390 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of AnaptysBio by 134.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,896 shares of the biotechnology company’s stock worth $106,000 after buying an additional 3,381 shares during the period. Finally, Algert Global LLC boosted its position in shares of AnaptysBio by 40.2% during the third quarter. Algert Global LLC now owns 16,530 shares of the biotechnology company’s stock worth $297,000 after buying an additional 4,740 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.